Latest Mesoblast (ASX:MSB) News

Biotech funding and regulatory setbacks drove the week’s biggest healthcare share moves, while larger companies delivered stronger earnings and deal activity. Telix’s proposed ITM takeover, Ramsay’s demerger plans and a mixed group of clinical updates kept investors focused on cash, approvals and sales.

Mesoblast has secured FDA approval to add a new potency assay to commercial release and stability testing for Ryoncil, its approved cell therapy for paediatric graft-versus-host disease. The regulatory decision supports tighter monitoring as manufacturing processes evolve, but the company disclosed no direct financial impact or clinical outcome data.

Healthcare shares delivered a mixed week, with strong gains at AVITA Medical, Australian Clinical Labs and CSL despite very different company results.
Investors also weighed new US approvals, clinical trial progress, funding needs and rising sales across the sector.

Mesoblast has treated 350 patients in its pivotal Phase 3 trial for rexlemestrocel-L, targeting chronic low back pain linked to degenerative disc disease, setting the stage for top-line results in mid-2027.

Xenitra led the healthcare board after a three-year Chinese pharmaceutical deal, while Artrya and InteliCare delivered the week’s biggest contrasting moves. Across the sector, companies raised cash, won regulatory support and pushed deeper into US hospitals and clinics.

Mesoblast delivered US$115 million in Ryoncil® revenue in its first full year post-FDA approval, while expanding clinical trials into adult indications and acquiring cutting-edge CAR technology to boost its cell therapy pipeline.

Big price swings hit healthcare stocks this week, but the sharpest falls did not always match the news flow. Revenue growth, trial progress and fresh US deals kept buying interest alive across parts of the sector.

Mesoblast has completed treatment of 300 patients in its pivotal Phase 3 trial for rexlemestrocel-L, targeting chronic low back pain due to degenerative disc disease, with topline results expected mid-2027.

Healthcare stocks swung hard this week as debt clean-ups, fresh funding and product sales updates drove the biggest moves. The strongest gains came from companies with clear near-term cash or commercial news, while some early spikes faded once trading settled.

Mesoblast Limited’s Ryoncil® posted US$36 million in Q4 revenue, driving a full-year total of US$115 million, exceeding initial forecasts. The FDA-approved stem cell therapy for pediatric graft-versus-host disease shows robust uptake across US pediatric centres.

Cann Group, OncoSil and Imugene led a busy healthcare week as investors chased FDA steps, cancer trial news and balance-sheet fixes. Elsewhere, revenue growth, hospital contracts and fresh funding kept money flowing into names with near-term commercial milestones.

Mesoblast has received a Biologics License Application filing number from the FDA for rexlemestrocel-L, targeting life-threatening bleeding in end-stage heart failure patients with LVADs, advancing its regulatory journey with orphan drug and RMAT designations.